دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Ambulatory Blood Pressure in Kidney Transplant Recipients: More Questions than Answers
Rai N.K. · Drawz P.E.
doi : 10.1159/000517359
Am J Nephrol 2021;52:519–521
Small Intestinal Phosphate Absorption: Novel Therapeutic Implications
Yee J.a · Rosenbaum D.b · Jacobs J.W.b · Sprague S.M.c
doi : 10.1159/000518110
Am J Nephrol 2021;52:522–530
Chronic kidney disease (CKD) affects approximately 15% of adults in the USA. As CKD progresses, urinary phosphate excretion decreases and results in phosphate retention and, eventually, hyperphosphatemia. As hyperphosphatemia is associated with numerous adverse outcomes, including increased cardiovascular mortality, reduction in phosphorus concentrations is a guideline-recommended, established clinical practice. Dietary phosphate restriction, dialysis, and phosphate binders are currently the only options for phosphate management. However, many patients with hyperphosphatemia have phosphorus concentrations >5.5 mg/dL, despite treatment.
Accuracy of Anti-GBM Antibodies in Diagnosing Anti-Glomerular Basement Membrane Disease: A Systematic Review and Meta-Analysis
Shiroshita A.a,b · Oda Y.c · Takenouchi S.d · Hagino N.e · Kataoka Y.b,f,g
doi : 10.1159/000518362
Am J Nephrol 2021;52:531–538
The sensitivity and specificity of anti-glomerular basement membrane (GBM) antibodies have not been systematically analyzed. In this systematic review, we aimed to evaluate the diagnostic accuracy of anti-GBM antibodies for anti-GBM disease.
Association of Dyskalemias with Ischemic Stroke in Advanced Chronic Kidney Disease Patients Transitioning to Dialysis
Dashputre A.A.a,b · Sumida K.b · Thomas F.c · Gatwood J.d · Akbilgic O.e · Potukuchi P.K.a,b · Obi Y.b · Molnar M.Z.f · Streja E.g · Kalantar Zadeh K.g · Kovesdy C.P.b,h
doi : 10.1159/000516902
Am J Nephrol 2021;52:539–547
Hypo- and hyperkalemia are associated with a higher risk of ischemic stroke. However, this association has not been examined in an advanced chronic kidney disease (CKD) population.
Diagnostic Performance of Office versus Ambulatory Blood Pressure in Kidney Transplant Recipients
Korogiannou M.a · Sarafidis P.b · Theodorakopoulou M.P.b · Alexandrou M.-E.b · Xagas E.a · Boletis I.N.a · Marinaki S.a
doi : 10.1159/000517358
Am J Nephrol 2021;52:548–558
Hypertension is the most prominent risk factor in kidney transplant recipients (KTRs). No study so far assessed in parallel the prevalence, control, and phenotypes of blood pressure (BP) or the accuracy of currently recommended office BP diagnostic thresholds in diagnosing elevated ambulatory BP in KTRs.
Prognostic and Diagnostic Values of Novel Serum and Urine Biomarkers in Lupus Nephritis: A Systematic Review
Radin M.a · Miraglia P.a,b · Barinotti A.a,b · Fenoglio R.c · Roccatello D.a,c · Sciascia S.a,c
doi : 10.1159/000517852
Am J Nephrol 2021;52:559–571
While renal biopsy remains the gold standard for diagnosing lupus nephritis (LN), the prognostic and diagnostic role of non-invasive biomarkers for LN is currently debated.
Ferric Citrate Dosing in Iron Deficiency Anemia in Nondialysis-Dependent Chronic Kidney Disease
Pergola P.E.a · Belo D.b · Crawford P.c · Moustafa M.d · Luo W.e · Goldfarb-Rumyantzev A.e · Farag Y.M.K.e
doi : 10.1159/000516012
Am J Nephrol 2021;52:572–581
Ferric citrate (FC) is indicated as an oral iron replacement for iron deficiency anemia in adult patients with chronic kidney disease (CKD) not on dialysis. The recommended starting dose is one 1-g tablet three times daily (TID). This study investigated long-term efficacy and safety of different FC dosing regimens for treating anemia in nondialysis-dependent CKD (NDD-CKD).
Urinary Kringle Domain-Containing Protein HGFL: A Validated Biomarker of Early Sickle Cell Anemia-Associated Kidney Disease
Nekhai S.a,b,c · Lin X.b,d · Soni S.c · Taye A.c · Smith N.c · Afangbedji N.b · Saraf S.L.e · Gordeuk V.R.e · Taylor J.G.b,c · Jerebtsova M.a
doi : 10.1159/000517056
Am J Nephrol 2021;52:582–587
Chronic kidney disease (CKD) is a prevalent complication of sickle cell anemia (SCA). Hyperfiltration that delayed detection of CKD is common in SCA patients. Identification of novel urinary biomarkers correlating with glomerular filtration rates may help to detect and predict progression of renal disease.
Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis
Droebner K.a · Pavkovic M.b · Grundmann M.a · Hartmann E.c · Goea L.a · Nordlohne J.a · Klar J.a · Eitner F.a · Kolkhof P.a
doi : 10.1159/000518254
Am J Nephrol 2021;52:588–601
The nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone and sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated clinical benefits in chronic kidney disease patients with type 2 diabetes. Precise molecular mechanisms responsible for these benefits are incompletely understood. Here, we investigated potential direct anti-fibrotic effects and mechanisms of nonsteroidal MR antagonism by finerenone or SGLT2 inhibition by empagliflozin in 2 relevant mouse kidney fibrosis models: unilateral ureter obstruction and sub-chronic ischemia reperfusion injury.
Transplant Risk Assessment: It Is Not about the Panel Reactive Antibodies
Daoud A.a · Nassar M.b
doi : 10.1159/000517814
Am J Nephrol 2021;52:602–603
Retraction Statement
Paper by Huifang Liu, Jiachuan Xiong, Ting He, Tangli Xiao, Yan Li, Yanlin Yu, Yinghui Huang, Xinli Xu, Yunjian Huang, Jingbo Zhang, Bo Zhang, and Jinghong Zhao
doi : 10.1159/000519103
Am J Nephrol 2021;52:604
